Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology

Lead clinical-stage program,OLN324, is a higher potency VEGF/Ang2 bispecific antibody in a fully-recruited head-to-head study versus faricimab in wet AMD and DME, with topline data expected Q1 2026